Codexis (CDXS) Non-Current Deffered Revenue (2010 - 2026)
Codexis' (CDXS) quarterly Non-Current Deffered Revenue came in at $350000.0 in Q1 2026, down 28.57% year-on-year from $490000.0 in Q1 2025, and down 2.78% quarter-over-quarter from $360000.0 in Q4 2025.
Codexis (CDXS) Non-Current Deffered Revenue (2010 - 2026) Analysis & Trends
Codexis' Non-Current Deffered Revenue history runs 17 years deep, the most recent figure standing at $350000.0 for Q1 2026.
- On a quarterly basis, Non-Current Deffered Revenue fell 28.57% year-over-year to $350000.0 in Q1 2026; TTM through Mar 2026 was $350000.0, a 28.57% decrease from a year earlier, with the FY2025 full-year figure at $360000.0, up 260.0% from the prior year.
- Non-Current Deffered Revenue slipped to $350000.0 in Q1 2026 per CDXS's latest filing, from $360000.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $16.9 million in Q4 2022 and bottomed at $100000.0 in Q4 2024.
- The 5-year median for Non-Current Deffered Revenue is $630000.0 (2024), against an average of $4.2 million.
- Across the five-year window, Non-Current Deffered Revenue soared 350.28% in 2022 and tumbled 98.02% in 2024, its largest moves.
- Year by year, Non-Current Deffered Revenue stood at $16.9 million in 2022, then tumbled by 96.21% to $640000.0 in 2023, then sank by 84.38% to $100000.0 in 2024, then soared by 260.0% to $360000.0 in 2025, then declined by 2.78% to $350000.0 in 2026.
- Per Business Quant, the three latest CDXS Non-Current Deffered Revenue figures stand at $350000.0 (Q1 2026), $360000.0 (Q4 2025), and $100000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,719.23 Bn | 65,718.94 Bn | - | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.85 Bn | 467.06 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.29 Bn | 115.04 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.28 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.47 Bn | 959.66 Mn | - |
| 10 | Codexis | 141.60 Mn | 76.46 Mn | 13.18 Mn | 350,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 350,000.00 |
| Dec 31, 2025 | 360,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Mar 31, 2025 | 490,000.00 |
| Dec 31, 2024 | 100,000.00 |
| Sep 30, 2024 | 610,000.00 |
| Jun 30, 2024 | 200,000.00 |
| Mar 31, 2024 | 630,000.00 |
| Dec 31, 2023 | 640,000.00 |
| Sep 30, 2023 | 10.10 Mn |
| Jun 30, 2023 | 10.11 Mn |
| Mar 31, 2023 | 15.51 Mn |
| Dec 31, 2022 | 16.88 Mn |
| Sep 30, 2022 | 8.24 Mn |
| Jun 30, 2022 | 3.15 Mn |
| Mar 31, 2022 | 3.46 Mn |
| Dec 31, 2021 | 3.75 Mn |
| Sep 30, 2021 | 3.75 Mn |
| Jun 30, 2021 | 3.17 Mn |